Chemosensitisation of malignant melanoma by BCL2 antisense therapy. | Lancet;356(9243): 1728-33, 2000 Nov 18. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Chemosensitisation of malignant melanoma by BCL2 antisense therapy.

Jansen, B; Wacheck, V; Heere-Ress, E; Schlagbauer-Wadl, H; Hoeller, C; Lucas, T; Hoermann, M; Hollenstein, U; Wolff, K; Pehamberger, H.

Affiliation

Jansen B; Department of Dermatology, University of Vienna, Vienna General Hospital, Austria. burkhard.jansen@univie.ac.at

Lancet ; 356(9243): 1728-33, 2000 Nov 18.

Article in En | MEDLINE | ID: mdl-11095261

Subject(s)

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: DNA, Antisense / Proto-Oncogene Proteins c-bcl-2 / Melanoma Type of study: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Lancet Year: 2000 Document type: Article Affiliation country: Austria Country of publication: Reino Unido

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: DNA, Antisense / Proto-Oncogene Proteins c-bcl-2 / Melanoma Type of study: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Lancet Year: 2000 Document type: Article Affiliation country: Austria Country of publication: Reino Unido